Stem-cell line

Global Stem Cell Manufacturing Market (2021 to 2026) - Supportive Regulatory Framework Across Developing Countries Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021

The Global Stem Cell Manufacturing Market is projected to reach USD 18 billion by 2026 from USD 11.5 billion in 2021, at a CAGR of 9.4% during the forecast period.

Key Points: 
  • The Global Stem Cell Manufacturing Market is projected to reach USD 18 billion by 2026 from USD 11.5 billion in 2021, at a CAGR of 9.4% during the forecast period.
  • The Stem Cell Manufacturing market by product is categorized into consumables, instruments, and stem cell lines.
  • The large share of this segment can be attributed to the frequent purchase of consumables, rising stem cell research, and increasing demand for stem cell therapies.
  • North America accounted for the largest share of the Stem Cell Manufacturing market.

Asymmetrex Introduces Therapeutic Stem Cell Dosage Technologies to Biotherapeutics Bioprocessing Companies

Retrieved on: 
Thursday, May 20, 2021

The simple answer he gave was that, "For the past 60+ years of stem cell medicine, there has been no way to determine the stem cell dosage of stem cell treatments.

Key Points: 
  • The simple answer he gave was that, "For the past 60+ years of stem cell medicine, there has been no way to determine the stem cell dosage of stem cell treatments.
  • Now that Asymmetrex\'s kinetics stem cell (KSC) counting technology makes it possible to determine the specific dosage of all therapeutic tissue stem cells, it just makes good science, good medicine, and good sense to start using stem cell-specific dosage.
  • "\nIn addition to addressing the long unmet need for knowing the stem cell dosage of tissue stem cell treatments and gene therapy treatments, which target tissue stem cells, Sherley discussed how technologies that quantify tissue stem cells specifically also had high impact applications for pharmaceutical and biopharmaceutical drug evaluations.
  • Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, April 28, 2021

b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.

Key Points: 
  • b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.
  • However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.\nThe adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020.\nBased on the cell source from which stem cells are obtained, the global market is segmented into four sources.
  • These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines).
  • In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries.

Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, April 28, 2021

b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.

Key Points: 
  • b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.
  • However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.\nThe adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020.\nBased on the cell source from which stem cells are obtained, the global market is segmented into four sources.
  • These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines).
  • In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries.

FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies

Retrieved on: 
Wednesday, March 17, 2021

As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.

Key Points: 
  • As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.
  • Under the agreement, FUJIFILM Cellular Dynamics grants Sana a non-exclusive license under intellectual property rights owned or controlled by FUJIFILM Cellular Dynamics, and will provide iPSC cell lines (including research-grade and/or Good Manufacturing Practices (GMP)-grade iPSC lines) to Sana.
  • FUJIFILM Cellular Dynamics is a leading global player in the field of iPSCs.
  • FUJIFILM Cellular Dynamics, Inc. is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery, contract development and manufacturing services, and cell therapies.

India Stem Cell Market Competition Forecast & Opportunities, 2026 by Product Type (Adult; Induced Pluripotent; Human Embryonic), Application (Regenerative Medicine Vs. Drug Discovery & Development) - ResearchAndMarkets.com

Retrieved on: 
Monday, February 15, 2021

The "India Stem Cell Market, By Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), By Application (Regenerative Medicine Vs. Drug Discovery & Development), By End User, By Technology, By Region, Competition Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Stem Cell Market, By Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), By Application (Regenerative Medicine Vs. Drug Discovery & Development), By End User, By Technology, By Region, Competition Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Indian Stem Cell Market was valued at USD 0.47 Billion in 2019 and is projected to grow at around 13% CAGR during FY 2021 - FY 2026.
  • Continuous advancements in tissue engineering is one of the prime factors boosting the Indian Stem Cell Market.
  • The Indian Stem Cell Market is segmented based on product type, application, technology, end-user and region.

India Stem Cell Market to 2026 by Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), & Application (Regenerative Medicine Vs. Drug Discovery & Development) - ResearchAndMarkets.com

Retrieved on: 
Friday, November 27, 2020

The "India Stem Cell Market by Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), by Application (Regenerative Medicine Vs. Drug Discovery & Development), by Technology, by Region, Competition Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Stem Cell Market by Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), by Application (Regenerative Medicine Vs. Drug Discovery & Development), by Technology, by Region, Competition Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Indian Stem Cell Market is expected to grow at over 12% CAGR during FY 2021 - FY 2026.
  • Continuous advancements in tissue engineering is one of the prime factors boosting the Indian Stem Cell Market.
  • The Indian Stem Cell Market is segmented based on product type, application, technology, and region.

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome

Retrieved on: 
Wednesday, October 28, 2020

This ultimately led to research and commercial sublicense agreements for the ESI-053 ESC line by ImStem to develop IMS001 as an allogeneic, off-the-shelf and industrially scalable MSC product candidate.

Key Points: 
  • This ultimately led to research and commercial sublicense agreements for the ESI-053 ESC line by ImStem to develop IMS001 as an allogeneic, off-the-shelf and industrially scalable MSC product candidate.
  • IMS001 is believed to be the first MSC product derived from an ESC line to be accepted for a human trial by the FDA.
  • We are glad to expand our relationship with ImStem, so it can now utilize AgeXs ESI-053 stem cell line to develop its cell therapy candidate IMS001 for COVID-19 as well as acute respiratory distress syndrome more broadly, said Dr. Nafees Malik, Chief Operating Officer of AgeX.
  • The ESI stem cell lines are distinguished as the first clinical-grade human pluripotent stem cell lines created under current Good Manufacturing Practice as described in Cell Stem Cell (2007;1:490-4).

AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes

Retrieved on: 
Wednesday, September 9, 2020

In particular, Lineage has acquired exclusivity for the use of ESI cell lines in spinal cord injury and certain oncology indications.

Key Points: 
  • In particular, Lineage has acquired exclusivity for the use of ESI cell lines in spinal cord injury and certain oncology indications.
  • The ESI cell lines are recognized for being the first clinical-grade human pluripotent stem cell lines created under cGMP as described in the publication Cell Stem Cell (2007;1:490-4).
  • These cell lines are listed on the NIH Stem Cell Registry and are among the best characterized and documented stem cell lines available globally.
  • These ESI cell lines are extensively characterized and most of the lines have documented and publicly available genomic sequences.

Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes

Retrieved on: 
Wednesday, September 9, 2020

In particular, Lineage has acquired exclusivity for the use of ESI cell lines in spinal cord injury and certain oncology indications.

Key Points: 
  • In particular, Lineage has acquired exclusivity for the use of ESI cell lines in spinal cord injury and certain oncology indications.
  • The ESI cell lines are recognized for being the first clinical-grade human pluripotent stem cell lines created under cGMP as described in the publication Cell Stem Cell (2007;1:490-4).
  • These cell lines are listed on the NIH Stem Cell Registry and are among the best characterized and documented stem cell lines available globally.
  • These ESI cell lines are extensively characterized and most of the lines have documented and publicly available genomic sequences.